AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)
< 1 minute read
Sep. 18, 2021
AG-636: A Dihydroorotate Dehydrogenase Inhibitor
AG-636
dihydroorotate dehydrogenase inhibitor in Ph. I for RR-lymphoma from opt. of literature molecule Mol. Cancer Ther., Oct. 20, 2020 Agios Pharmaceuticals, Cambridge, MA